JP2015520143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520143A5 JP2015520143A5 JP2015510822A JP2015510822A JP2015520143A5 JP 2015520143 A5 JP2015520143 A5 JP 2015520143A5 JP 2015510822 A JP2015510822 A JP 2015510822A JP 2015510822 A JP2015510822 A JP 2015510822A JP 2015520143 A5 JP2015520143 A5 JP 2015520143A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- alkoxy
- formula
- attachment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CC1(*)C=NC=CC(N(*)c2c(*)c(*)nc(-c3n[n]c4c3CCCC43CCCC3)n2)=C1 Chemical compound CC1(*)C=NC=CC(N(*)c2c(*)c(*)nc(-c3n[n]c4c3CCCC43CCCC3)n2)=C1 0.000 description 1
- ADNXCHQUIPXULO-UHFFFAOYSA-O CCOC(c1cnccc1[OH2+])=O Chemical compound CCOC(c1cnccc1[OH2+])=O ADNXCHQUIPXULO-UHFFFAOYSA-O 0.000 description 1
- JZTKRFAEIHYBNV-UHFFFAOYSA-O CN[O](CC[OH2+])(=O)=O Chemical compound CN[O](CC[OH2+])(=O)=O JZTKRFAEIHYBNV-UHFFFAOYSA-O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167690.2 | 2012-05-11 | ||
| EP12167690 | 2012-05-11 | ||
| PCT/EP2013/059666 WO2013167698A1 (en) | 2012-05-11 | 2013-05-08 | Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015520143A JP2015520143A (ja) | 2015-07-16 |
| JP2015520143A5 true JP2015520143A5 (enExample) | 2016-07-07 |
Family
ID=48407563
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015510822A Ceased JP2015520143A (ja) | 2012-05-11 | 2013-05-08 | 癌を治療するためのｂｕｂ１阻害薬としての置換されているシクロアルケノピラゾール類 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20150141372A1 (enExample) |
| EP (1) | EP2847180B1 (enExample) |
| JP (1) | JP2015520143A (enExample) |
| CN (1) | CN104411701B (enExample) |
| CA (1) | CA2872933A1 (enExample) |
| ES (1) | ES2620316T3 (enExample) |
| HK (1) | HK1207861A1 (enExample) |
| WO (1) | WO2013167698A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA111754C2 (uk) | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| ES2638144T3 (es) | 2011-12-21 | 2017-10-18 | Bayer Intellectual Property Gmbh | Bencilpirazoles sustituidos |
| US20160046610A1 (en) * | 2013-03-21 | 2016-02-18 | Bayer Pharma Aktiengesellschaft | 3-heteroaryl substituted indazoles |
| HK1223350A1 (zh) * | 2013-03-21 | 2017-07-28 | Bayer Pharma Aktiengesellschaft | 杂芳基取代的吲唑 |
| US20160052912A1 (en) * | 2013-03-21 | 2016-02-25 | Bayer Pharma Akitiengesellschaft | Diaminoheteroaryl substituted indazoles |
| CN105452237A (zh) | 2013-06-21 | 2016-03-30 | 拜耳制药股份公司 | 杂芳基取代的吡唑 |
| EP3010904A1 (en) | 2013-06-21 | 2016-04-27 | Bayer Pharma Aktiengesellschaft | Substituted benzylpyrazoles |
| CN105473570A (zh) * | 2013-06-21 | 2016-04-06 | 拜耳制药股份公司 | 二氨基杂芳基取代的吡唑 |
| CA2928998A1 (en) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Heteroaryl substituted pyrazoles |
| ES2708211T3 (es) * | 2014-06-17 | 2019-04-09 | Bayer Pharma AG | 3-amino-1,5,6,7-tetrahidro-4H-indol-4-onas |
| MX2017003664A (es) | 2014-09-19 | 2017-07-13 | Bayer Pharma AG | Indazoles sustituidos con benzilo como inhibidores de bub1. |
| AU2016212230B2 (en) | 2015-01-28 | 2019-09-19 | Bayer Pharma Aktiengesellschaft | 4H-pyrrolo[3,2-c]pyridin-4-one derivatives |
| US10227299B2 (en) | 2015-06-17 | 2019-03-12 | Bayer Pharma Aktiengesellschaft | 3-amino-1,5,6,7-tetrahydro-4H-indol-4-ones |
| CA2994596A1 (en) * | 2015-08-05 | 2017-02-09 | Bayer Pharma Aktiengesellschaft | 1h-pyrrol-3-amines |
| JP2019504826A (ja) * | 2015-12-16 | 2019-02-21 | バイエル ファーマ アクチエンゲゼルシャフト | ヘテロ−１，５，６，７−テトラヒドロ−４ｈ−インドール−４−オン類 |
| WO2017148995A1 (en) | 2016-03-04 | 2017-09-08 | Bayer Pharma Aktiengesellschaft | 1-(pyrimidin-2-yl)-1h-indazoles having bub1 kinase inhibiting activity |
| WO2017157991A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | 1-alkyl-pyrazoles and -indazoles as bub1 inhibitors for the treatment of hyperproliferative diseases |
| WO2017157992A1 (en) | 2016-03-18 | 2017-09-21 | Bayer Pharma Aktiengesellschaft | Annulated pyrazoles as bub1 kinase inhibitors for treating proliferative disorders |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018158175A1 (en) | 2017-02-28 | 2018-09-07 | Bayer Pharma Aktiengesellschaft | Combination of bub1 inhibitors |
| WO2018206547A1 (en) | 2017-05-12 | 2018-11-15 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and atr inhibitors |
| WO2018215282A1 (en) | 2017-05-26 | 2018-11-29 | Bayer Pharma Aktiengesellschaft | Combination of bub1 and pi3k inhibitors |
| CA3196712A1 (en) | 2020-09-23 | 2022-03-31 | Scorpion Therapeutics, Inc. | Pyrrolo[3,2-c]pyridin-4-one derivatives useful in the treatment of cancer |
| WO2022072645A2 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022072634A1 (en) | 2020-09-30 | 2022-04-07 | Scorpion Therapeutics, Inc. | Bicyclic compounds for use in the treatment cancer |
| TW202227063A (zh) | 2020-10-09 | 2022-07-16 | 美商史考皮恩治療有限公司 | 治療癌症之方法 |
| WO2022094271A1 (en) | 2020-10-30 | 2022-05-05 | Scorpion Therapeutics, Inc. | Methods for treating cancer |
| WO2022098992A1 (en) | 2020-11-05 | 2022-05-12 | Scorpion Therapeutics, Inc. | Use of macrocyclic compounds in methods of treating cancer |
| WO2022197913A1 (en) | 2021-03-18 | 2022-09-22 | Scorpion Therapeutics, Inc. | Bicyclic derivatives which can be used to treat cancer |
| WO2023173083A1 (en) | 2022-03-11 | 2023-09-14 | Scorpion Therapeutics, Inc. | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer |
| EP4293019A1 (en) * | 2022-06-13 | 2023-12-20 | Netherlands Translational Research Center Holding B.V. | 4-substituted (1h-benzo[d]imidazol-2-yl)-1h-pyrazoles as bub1 inhibitors useful for treating cancers |
| CN116036121B (zh) * | 2022-12-16 | 2024-10-18 | 福州载基生物科技有限公司 | 人bub1基因在制备抗肿瘤药物中的用途 |
| EP4724151A1 (en) | 2023-06-08 | 2026-04-15 | Antares Therapeutics, Inc. | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer |
| CN121712773A (zh) | 2023-06-08 | 2026-03-20 | 安塔列斯疗法股份有限公司 | 1,5-二氢-4h-吡咯并[3,2-c]吡啶-4-酮用于癌症治疗 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5011472A (en) | 1988-09-06 | 1991-04-30 | Brown University Research Foundation | Implantable delivery system for biological factors |
| GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| WO2001058857A1 (de) | 2000-02-10 | 2001-08-16 | Lonza Ag | Verfahren zur herstellung von alkoxymalonsäuredinitrilen |
| AU2002228922A1 (en) * | 2000-12-12 | 2002-06-24 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US20050209252A1 (en) * | 2002-03-29 | 2005-09-22 | Che-Ming Teng | Cancer treatment |
| FR2875230A1 (fr) * | 2004-09-13 | 2006-03-17 | Sanofi Aventis Sa | Derives de pyrazole condense, leur preparation et leur application en therapeutique |
| US20090263398A1 (en) * | 2006-07-14 | 2009-10-22 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US20130178475A1 (en) * | 2010-03-17 | 2013-07-11 | Ironwood Pharmaceuticals, Inc. | sGC STIMULATORS |
| UA111754C2 (uk) * | 2011-10-06 | 2016-06-10 | Байєр Фарма Акцієнгезелльшафт | Заміщені бензиліндазоли для застосування як інгібіторів bub1-кінази для лікування гіперпроліферативних захворювань |
| EP2594270A3 (en) * | 2011-11-18 | 2013-07-31 | BIP Patents | The use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) |
-
2013
- 2013-05-08 HK HK15108514.3A patent/HK1207861A1/xx unknown
- 2013-05-08 CA CA2872933A patent/CA2872933A1/en not_active Abandoned
- 2013-05-08 JP JP2015510822A patent/JP2015520143A/ja not_active Ceased
- 2013-05-08 ES ES13721755.0T patent/ES2620316T3/es active Active
- 2013-05-08 CN CN201380036066.XA patent/CN104411701B/zh not_active Expired - Fee Related
- 2013-05-08 EP EP13721755.0A patent/EP2847180B1/en not_active Not-in-force
- 2013-05-08 US US14/400,315 patent/US20150141372A1/en active Granted
- 2013-05-08 WO PCT/EP2013/059666 patent/WO2013167698A1/en not_active Ceased
-
2017
- 2017-03-08 US US15/453,679 patent/US20170275267A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2989617T3 (es) | Moduladores de receptores de quimioquinas y usos de los mismos | |
| ES2810852T3 (es) | Compuestos y composiciones para inhibir la actividad de shp2 | |
| JP6523303B2 (ja) | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 | |
| EP4045498B1 (en) | Broad spectrum anti-cancer compounds | |
| ES2824576T3 (es) | Compuestos y composiciones para inhibir la actividad de SHP2 | |
| RU2018129308A (ru) | Новые производные аммония, способ их получения и фармацевтические композиции, содержащие их | |
| RU2018102365A (ru) | Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их | |
| JP2018533611A5 (enExample) | ||
| JP2019521988A5 (enExample) | ||
| JP2021510376A5 (enExample) | ||
| WO2015157115A1 (en) | Mertk-specific pyrimidine compounds | |
| RU2014151850A (ru) | Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их | |
| JP2016525075A5 (enExample) | ||
| JP2016525076A5 (enExample) | ||
| JP2021502345A (ja) | 抗がん剤 | |
| CA2653941A1 (en) | Substituted amino purine derivatives and uses thereof | |
| UA119028C2 (uk) | Функціоналізовані на n-кінці амінокислотні похідні, здатні утворювати мікросфери, що інкапсулюють лікарський засіб | |
| JP2012520861A5 (enExample) | ||
| JP2021501756A5 (enExample) | ||
| JP2016503414A5 (enExample) | ||
| JP2015512943A5 (enExample) | ||
| JP2017524733A5 (enExample) | ||
| CN116848106A (zh) | 作为cbl-b抑制剂的酰胺 | |
| TWI757726B (zh) | 4(1h)-奎諾酮衍生物及其用途 | |
| IL303472A (en) | Alk-5 inhibitors and uses thereof |